Article

Caracterização clínico-epidemiológica dos pacientes com diagnóstico de tuberculose resistente às drogas em João Pessoa, PB

Revista Eletronica de Enfermagem 01/2008;
Source: DOAJ

ABSTRACT A resistência aos esquemas usuais de tratamento à tuberculose (TB) tem sido um fenômeno preocupante principalmente nos países em desenvolvimento, agravado pela miséria, co-infecção TB/HIV, degradação dos serviços de saúde. Objetivou-se descrever as características clínico-epidemiológicas dos pacientes que desenvolveram resistência aos tuberculostáticos, assistidos em hospital de referência em João Pessoa, PB. Pesquisa documental retrospectiva constituída por 22 prontuários de pacientes acompanhados entre 2002 a 2006, que utilizou um formulário para coleta de dados. Os resultados revelaram que 77% dos casos encontravam-se na faixa etária de 36 a 55 anos; 72,5% do sexo masculino; 55% solteiro/separado; 77% possuíam baixa escolaridade; 64% renda familiar inferior a um salário mínimo. Quanto à caracterização clínica, 100% apresentavam forma clínica pulmonar e resistência a isoniazida; 73% resistentes a isoniazida, rifampicina e a uma terceira droga; 40% à pirazinamida. Além da resistência às drogas de primeira e segunda linha, observou-se resistência a clofazimina, droga utilizada para tratamento de casos multirresistentes. Chama atenção, que 95% dos casos tinham história de tratamento anterior, sugerindo a necessidade de adoção de medidas que aumentem o rendimento das ações de controle da TB, em especial à implementação da supervisão terapêutica para casos sensíveis, evitando o aparecimento da resistência.

0 Bookmarks
 · 
220 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Resistance to antituberculosis drugs has been a problem since the era of chemotherapy began. After dramatic outbreaks of multidrug-resistant tuberculosis (MDR-TB) in the early 1990s, resistance became recognized as a global problem. MDR-TB now threatens the inhabitants of countries in Europe, Asia, Africa, and the Americas. An understanding of the molecular basis of drug resistance may contribute to the development of new drugs. Management of MDR-TB relies on prompt recognition and treatment with at least 3 drugs to which an isolate is susceptible.
    Clinical Infectious Diseases 02/2003; 36(Suppl 1):S24-30. · 9.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study sought to determine the impact of the World Health Organization's directly observed treatment strategy (DOTS) compared with that of DOTS-plus on tuberculosis deaths, mainly in the developing world. Decision analysis with Monte Carlo simulation of a Markov decision tree. People with smear positive pulmonary tuberculosis. Analyses modelled different levels of programme effectiveness of DOTS and DOTS-plus, and high (10%) and intermediate (3%) proportions of primary multidrug resistant tuberculosis, while accounting for exogenous reinfection. The cumulative number of tuberculosis deaths per 100 000 population over 10 years. The model predicted that under DOTS, 276 people would die from tuberculosis (24 multidrug resistant and 252 not multidrug resistant) over 10 years under optimal implementation in an area with 3% primary multidrug resistant tuberculosis. Optimal implementation of DOTS-plus would result in four (1.5%) fewer deaths. If implementation of DOTS-plus were to result in a decrease of just 5% in the effectiveness of DOTS, 16% more people would die with tuberculosis than under DOTS alone. In an area with 10% primary multidrug resistant tuberculosis, 10% fewer deaths would occur under optimal DOTS-plus than under optimal DOTS, but 16% more deaths would occur if implementation of DOTS-plus were to result in a 5% decrease in the effectiveness of DOTS CONCLUSIONS: Under optimal implementation, fewer tuberculosis deaths would occur under DOTS-plus than under DOTS. If, however, implementation of DOTS-plus were associated with even minimal decreases in the effectiveness of treatment, substantially more patients would die than under DOTS.
    BMJ (online) 04/2003; 326(7389):574. · 17.22 Impact Factor
  • The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 02/1999; 3(1):1-3. · 2.61 Impact Factor

Full-text

View
2 Downloads
Available from